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Objectives: This study analyses the association between health-related quality 
of life (HRQL) domains and progression free (PFS) and overall survival (OS) for ipili-
mumab, ipilimumab + gp100, and gp100 alone during the 12 week treatment induc-
tion period compared to baseline. The aim of this study was to assess whether 
outcomes reported in the EORTC-QLQ-C30 summary domains impact the hazard 
of progressing and/or dying after 12 weeks of treatment. MethOds: Data from the 
MDX010-20 trial, including 676 previously treated patients with unresectable stage 
III or IV melanoma, was analysed. A domain correlation plot (excluding Global 
domain) was constructed to determine whether the EORTC-QLQ-C30 domains 
showed a high level of correlation for baseline scores. It was then used to derive 
two components summarising fourteen domain scores, Principal Components 
1, containing 10 domain scores (Pain, Appetite Loss, Nausea, Finance, Dyspnoea, 
Constipation, Diarrhoea, Role, Social and Physical) and 2 containing 4 domains 
scores (Fatigue, Sleep Disturbance, Emotional and Cognitive), based on the cor-
relation level between domains. These two Principal Components were entered as 
additional covariates in the Cox model for PFS/OS and hazard ratios were deter-
mined. Results: In the Cox regression model, Principal Component 1 showed a 
30% increase in hazard of progression when comparing the upper to the lower 
quartile of the Principal Component score , while a lower Principal Component 
1 score indicated a better HRQL at baseline. It was also showed a rate of death 
twice as high in the upper quartile than the lower quartile. Principal Component 
2 neither affected significantly PFS nor OS. cOnclusiOns: In advanced mela-
noma treated by ipilimumab compared to gp100, PFS and OS were associated with 
most of the HRQL domain scores. These findings suggest that poor baseline HRQL 
could be predictive of poor PFS/OS, while higher baseline HRQL could predict a 
better outcome.
PCN171
QuAlity of lifE (Qol) DuriNg trEAtmENt of NEwly DiAgNosED loCAlly 
CoNfiNED low-risk ProstAtE CANCEr (lClrPC) iN gErmANy: rEsults of 
thE hArow stuDy
Schädlich P.K.1, Baranek T.2, Häussler B.1, Weißbach L.3
1IGES Institut GmbH, Berlin, Germany, 2CSG - Clinische Studien Gesellschaft mbH, Berlin, 
Germany, 3Stiftung Männergesundheit - Foundation for Men’s Health, Berlin, Germany
Objectives: The optimal treatment choice for preserving QoL of the about 64,000 
men diagnosed with prostate cancer each year in Germany still remains unclear. The 
objectives therefore were to generate long-term information under day-to-day condi-
tions on QoL of men in Germany cared for newly diagnosed LCLRPC using hormonal 
therapy (HT), active surveillance (AS), radiotherapy (RT), operation (OP), or watch-
ful waiting (WW) – HAROW. MethOds: The long-term observational multi-centre 
HAROW study was undertaken. The urologist provided all relevant clinical data of 
the patient. The patient provided inter alia data on QoL using the EQ-5D. Utilities 
derived from the EQ-5D based on the German value set were used to construct quality-
adjusted life-years (QALYs). QALYs were discounted by 3% annually and standardised 
to mean QALYs per patient-year (PY) for each initial treatment strategy. Differences 
between strategies were tested using the Kruskal-Wallis test (Bonferroni-corrected 
p= 0.0018 due to 28 tests). Results: Between July 2008 and March 2013, 3063 patients 
(mean age 67.3 ± 7.5 years) with LCLRPC (T1a–T2c, N0, M0) were included from 257 
urologists. Data on QoL were documented by patients as follows (% of patients/strat-
egy): AS n= 353 (78%), RT n= 291 (77%), HT n= 149 (71%), HT+RT n= 68 (85%), combination 
therapy (CT) n= 109 (80%), OP n= 1167 (71%), other therapy (OT) n= 9 (50%), WW n= 93 
(66%), over a mean time of between 1.6 (OT) and 2.5 years (CT). AS showed the highest 
undiscounted/discounted QALYs/PY (0.9297/0.9103) followed by OP (0.9289/0.9075), 
RT (0.9075/0.8878), CT (0.9071/0.8820), OT (0.8954/0.8818), HT+RT (0.8875/0.8699), WW 
(0.8646/0.8465), and HT (0.8485/0.8292). Compared to HT, QALYs/PY were significantly 
higher with AS (p< 0.0001), with OP (p< 0.0001), and with RT (p= 0.0002). Tests with 
undiscounted/discounted QALYs/PY adjusted for age, tumor stage and comorbidity 
showed no different results. cOnclusiOns: According to the HAROW study, active 
surveillance yielded the highest QALYs of the different LCLRPC treatment strategies 
in Germany evaluated.
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Objectives: To explore how often and which types of quality of life (QOL) data are 
included in the dossiers submitted for the AMNOG early benefit assessment and 
analyze how a drug’s effect in QOL is interpreted by the industry and the evaluating 
committee. MethOds: The published value dossiers up to June 15, 2013 and the cor-
responding benefit assessments were reviewed. Types of QOL data and the statements 
concerning QOL in the value dossier and the benefit assessments were collected and 
summarized. Results: A total of 46 cases were analyzed. In 6 cases no dossier was 
submitted. Of the rest, 13 dossiers (32.5%) did not include any QOL data, 13 (32.5%) 
included disease-specific QOL data only, 5 (12.5%) included generic QOL data only, 
and 9 (22.5%) both types. The QOL instruments used were considered as valid by the 
assessors. However, outcomes such as pain severity, fatigue, work productivity, and 
health care resource use were not regarded as QOL measures. Of 27 dossiers that have 
included QOL data companies have claimed an added benefit in QOL, either for the 
whole population or a specific subgroup, in 15 (56%) cases. However, the assessors rec-
of care could be nowadays a major issue MethOds: This prospective study carried 
out in 12 Hospitals. At baseline patients fulfilled EQ-5D questionnaire (utility and 
VAS scale), EORTC-QLQ-C30 (physical, role, emotional, cognitive and social function-
ing, and global health) and HADS. One year post-surgical management they com-
pleted the EQ-5D and EORTC-QLQ-C30. We used general linear models to establish 
the influence of baseline anxiety (HADS-A) and depression (HADS-D) on changes in 
HRQoL, adjusted by baseline score and gender. We have used the recommended cut-
off points of HADS ≤ 7 (normal); 8-10 (uncertain) and ≥ 11 (problem). Results: There 
were 778 patients. The mean age (SD) was 67.4 (10.4). Males represented the 62.7%. 
At baseline, in the HADS-A there were 282 (36.4%) of patients scoring higher than 7 
points (17.6% higher than 10 points). In the HADS-D 137 (17.6%) scored higher than 7 
and 9.3% were higher than 10 points. Both anxiety and depression at baseline influ-
ence the changes in EQ-5D, with less gains in patients with more level of anxiety 
or depression (p< 0.0001). Regarding the EORTC-QLQ-C30 domains, baseline anxiety 
level impacts significantly in all domains, except in physical functioning, with gains 
around 5 to 11 points lower in patients with anxiety problems comparing with those 
classified as normal (all p< 0.05). Baseline depression level impacts significantly on 
changes in role and social functioning, and global health, with gains around 10 to 
13 points lower in patients with depression problems (all p< 0.01). cOnclusiOns: 
This study supports the importance of providing psychological interventions for 
cancer patients before surgical management.
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Objectives: To develop an unidimensional and short version of the QLQ-C30 to be 
used as a patient-perceived quality of life in cancer trials. MethOds: We analysed 
data of 873 patients diagnosed with non-small-cell lung cancer who participated 
in 4 Cuban multicenter trials of immunotherapy against the epidermal growth 
factor. The analysis followed a 4-step approach. First, we conducted a Mokken 
nonparametric item response analysis to ascertain the QLQ-C30 dimensionality 
and separate several scales if appropriate. Second, we conducted a parametric 
Samejima’s graded response model (GRM) to assess the item characteristics and 
information. Third, we did a confirmatory factor analysis (CFA) to test the scales 
unidimensionality and to obtain standardised factor loadings to suggest a reduced 
version of the QLQ. Finally, we assessed the discriminative validity of the reduced 
version by using receiver-operator curve (ROC) analysis. Results: Mokken analy-
sis of the QLQ-C30 resulted in a unidimensional scale, with an overall scalability 
of 0.43 that defined a medium scale. The unconstrained GRM showed that most 
items presented appropriate difficulty and discrimination parameters. The CFA 
supported an underlying unidimensional latent structure for the whole QLQ-C30 
(CFI = 0.98; RMSEA = 0.05) with modification indexes pointing to important redun-
dancy of information. The selection of items with standardized factor loadings 
> 0.70 lead to a 6-item QLQ that showed good discriminative validity against 
independent criteria of quality of life (ROC area = 0.76; 95% CI = 0.72 to 0.80) as 
compared with the values for the whole scale (ROC area = 0.70; 95% CI = 0.66 to 
0.74). cOnclusiOns: The EORTC QLQ-C6 suggested in this study presents good 
psychometric properties and includes an unidimensional structure of patient-
perceived quality of life.
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Objectives: To evaluate the burden of BM on patients with CRPC and their treat-
ing physicians. MethOds: A total of 167 physicians (100 oncologists and 67 urolo-
gists) completed a prospective 5-day workload form, interview and average of 8 
patient record forms (PRFs, October 2012–March 2013) for non-metastatic and 
metastatic CRPC patients. Data from 142 workload forms, 167 interviews and 1,274 
PRFs (including 475 CRPC patients at ‘high risk’ of BM, 505 CRPC patients with BM 
only, 102 CRPC patients with BM and VM and 192 CRPC patients with VM only) 
were included in these analyses. Results: Physician interviews showed 92%, 
63% and 60% of the physicians believed the greatest patient burden of BM was 
back pain, reduced ability to perform daily activities and fractures, respectively 
(from a predetermined list where ‘other’ was specified). PRF data confirmed that 
Eastern Cooperative Oncology Group (ECOG) performance status was significantly 
worse in patients with BM (with/without VM) when compared with patients at 
high-risk of developing BM (p< 0.0001). 92% of the patients at ‘high-risk’ (defined by 
treating physician) of developing BM (n= 475) had a PSA doubling time (PSADT) ≤ 6 
months. The biggest burden of BM on treating physicians was seeing patient dete-
rioration (70% [n= 117]; 67% of oncologists; 75% of urologists), inability to propose 
effective treatment (57% [n= 95]; 60% of oncologists; 52% of urologists), managing 
complex regimens (29% [n= 49]; 27% of oncologists; 33% of urologists) and trans-
ferring patients for respite/hospice care (23% [n= 38]; 26% of oncologists; 18% of 
urologists). cOnclusiOns: These data highlight the burden of BM on patients 
with CRPC and the perceived burden on physicians treating this population. BM 
are associated with a significant reduction in patients’ performance status and 
an increased burden on the patient. There is a need for treatments to prevent or 
delay the onset of BM and their associated burden.
